Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Study to Investigate BL-8040 in Combination with Pembrolizumab in Patients with Metastatic Pancreatic Cancer

Trial Profile

A Phase IIa Study to Investigate BL-8040 in Combination with Pembrolizumab in Patients with Metastatic Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motixafortide (Primary) ; Pembrolizumab (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 According to a BioLineRx media release, partial results are expected in H2 2017 and top-line results are expected in H2 2018.
    • 30 Jan 2017 New trial record
    • 17 Jan 2017 According to a BioLineRx media release, Dr. David Fogelman, from MD Anderson Cancer Center, is the principal investigator of the trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top